Evidence map›Paper›PMID 41993469›Full record

ArticlebioRxiv : the preprint server for biology2026

The COX2-PGE

Pham Thuy Tien Vo, Julien Cicero, Zichen Wang, Hiroyuki Hakozaki, Thomas S Hoang, Sendi Rafael Adame-Garcia, Dana J Ramms, Kuniaki Sato, Erica Stevenson, Yuan Zhou and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pham Thuy Tien VoMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Julien CiceroDepartment of Cell and Developmental Biology, School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.
Zichen WangDepartment of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
Hiroyuki HakozakiDepartment of Chemistry and Biochemistry, University of California, La Jolla, CA, UCA.
Thomas S HoangMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0003-1282-734X
Sendi Rafael Adame-GarciaMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Dana J RammsMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Kuniaki SatoMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-6014-1911
Erica StevensonQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.
Yuan ZhouQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.
Katie FanMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Danielle L SwaneyQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.
Nevan J KroganQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4902-337X
Johannes SchönebergDepartment of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
Uri ManorDepartment of Cell and Developmental Biology, School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-9802-1955
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.

Funding

The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emma Lundberg · 2022 to 2026
$14.2M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY · 2017 to 2021
$10.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Targeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7M
Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral CancerR01DE033909 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, Tracy M Handel · 2024 to 2026
$1.8M
Modeling and Analysis of the Spatio-Temporal Dynamics of the Mitochondrial NetworkR01GM148765 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Johannes Schoeneberg · 2023 to 2026
$1.2M
NCI NIH HHS T32 CA121938NCI NIH HHS U54 CA209891NCI NIH HHS U54 CA274502NIDCR NIH HHS R01 DE026644NIDCR NIH HHS R01 DE033909NIGMS NIH HHS R01 GM148765
6 · The paper itself

Abstract

The innate immune cGAS-STING pathway is activated by cytosolic double-stranded DNA (dsDNA) to induce type I interferon (IFN) response, which is essential for mounting the antiviral response. However, STING activation during viral infection is often insufficient to achieve complete viral clearance, suggesting the existence of additional mechanisms that evade its activity. Here, we identified COX2/PGE

Indexed as

antiviral innate immunitycAMPcGAS-STING pathwaycyclooxygenase-2 (COX2)G protein-coupled receptors (GPCRs)mitochondrial DNA (mtDNA)mitochondrial quality controlmitophagyProstaglandin E2 (PGE2)protein kinase A (PKA)type I interferon

Identifiers

PMID41993469
PMCPMC13082092

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.